|
| | Publication Year | Title | Author(s) |
| 1 | 7-Dec-2023 | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG. | Loo, Sun; Roberts, Andrew W; Anstee, Natasha S; Kennedy, Glen A; He, Simon Zhao-Xiong; Schwarer, Anthony P ; Enjeti, Anoop Kumar; D'Rozario, James; Marlton, Paula; Bilmon, Ian; Taper, John M; Cull, Gavin; Tiley, Campbell; Verner, Emma; Hahn, Uwe; Hiwase, Devendra K; Iland, Harry J; Murphy, Nicholas Edward; Ramanathan, Sundra; Reynolds, John; Ong, Doen Ming; Tiong, Ing Soo; Wall, Meaghan; Murray, Michael; Rawling, Tristan; Leadbetter, Joanna; Rowley, Leesa; Latimer, Maya; Yuen, Sam L S; Ting, Stephen B; Fong, Chun Yew ; Morris, Kirk Lachlan; Bajel, Ashish; Seymour, John F; Levis, Mark J; Wei, Andrew H |
| 2 | 1-Sep-2023 | Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. | Shanmuganathan, Naranie; Wadham, Carol; Shahrin, NurHezrin; Feng, Jinghua; Thomson, Daniel; Wang, Paul; Saunders, Verity; Kok, Chung Hoow; King, Rob M; Kenyon, Rosalie R; Lin, Ming; Pagani, Ilaria S; Ross, David M; Yong, Agnes S M; Grigg, Andrew P ; Mills, Anthony K; Schwarer, Anthony P ; Braley, Jodi; Altamura, Haley; Yeung, David T; Scott, Hamish S; Schreiber, Andreas W; Hughes, Timothy P; Branford, Susan |
| 3 | Jan-2023 | Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P ; Récher, Christian; Jonas, Brian A; Ferrell, P Brent; Marzac, Christophe; Kelly, Patrick; Sweeney, Jennifer; Forsyth, Sanjeev; Guichard, Sylvie M; Brevard, Julie; Henrick, Patrick; Mohamed, Hesham; Cortes, Jorge E |
| 4 | 26-Apr-2021 | The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia. | Rees, Matthew J ; Wu, Simon; Mokoonlall, Mridula; Dix, Caroline H K; Bryant, Christian E; D'Rozario, James; Schwarer, Anthony P ; Grigg, Andrew P ; Tiong, Ing S |
| 5 | Mar-2021 | Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. | Tiong, Ing S ; Dillon, Richard; Ivey, Adam; Teh, Tse-Chieh; Nguyen, Phillip; Cummings, Nicholas; Taussig, David C; Latif, Annie-Louise; Potter, Nicola E; Runglall, Manohursingh; Russell, Nigel H; Raj, Kavita; Schwarer, Anthony P ; Fong, Chun Yew ; Grigg, Andrew P ; Wei, Andrew H |
| 6 | 2021 | Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission. | Nguyen, Phillip C; Manos, Kate ; Fong, Chun Y; Schwarer, Anthony P ; Tiong, Ing S ; Wei, Andrew H; Kliman, David; Curtis, David J |
| 7 | 2021 | Acute graft-versus-host disease associated cerebellitis as the cause of pyrexia of unknown origin detected with 18F-FDG-PET/CT. | Jewell, Kerry E; Kuzich, James A; Lee, Sze Ting ; Trethowan, Rebecca; Macdonell, Richard A L ; Schwarer, Anthony P |
| 8 | Jul-2019 | Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. | Hamadi, Abdullah; Grigg, Andrew P ; Dobie, Gasim; Burbury, Kate L; Schwarer, Anthony P ; Kwa, Faith A; Jackson, Denise E |
| 9 | Dec-2018 | A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML. | Schwarer, Anthony P ; Butler, Jason; Jackson, Kathryn; Beligaswatte, Ashanka; Martin, Louisa; Kennedy, Glen; Daniela, Zantomio; Lewis, Ian; Hiwase, Devendra; Wight, Joel C ; He, Simon ; Grigg, Andrew; Morris, Kirk; Mollee, Peter; Marlton, Paula |
| 10 | 2018 | Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. | Ross, David M; Pagani, Ilaria S; Shanmuganathan, Naranie; Kok, Chung H; Seymour, John F; Mills, Anthony K; Filshie, Robin J; Arthur, Christopher K; Dang, Phuong; Saunders, Verity A; Braley, Jodi; Yong, Agnes S; Yeung, David T; White, Deborah L; Grigg, Andrew P ; Schwarer, Anthony P ; Branford, Susan; Hughes, Timothy P |
| 11 | Jun-2017 | Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era | Tamjid, Babak ; Mckendrick, Joseph; Schwarer, Anthony P ; Doig, Rowan; James, Philip; Hosking, Patrick; Hawkes, Eliza A |
| 12 | 23-May-2017 | The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. | Fox, Lucy C; Cummins, Katherine D; Costello, Ben; Yeung, David; Cleary, Rebecca; Forsyth, Cecily; Tatarczuch, Maciek; Burbury, Kate; Motorna, Olga; Shortt, Jake; Fleming, Shaun; McQuillan, Andrew; Schwarer, Anthony P ; Harrup, Rosemary; Holmes, Amy; Ratnasingam, Sumita; Chan, Kah-Lok; Hsu, Wei-Hsun; Ashraf, Asma; Putt, Faye; Grigg, Andrew P |
| 13 | Apr-2016 | Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era | Jalali, Azim; Ha, Francis J; Chong, Geoff; Grigg, Andrew P ; Mckendrick, Joe; Schwarer, Anthony P ; Doig, Rowan; Hamid, Anis; Hawkes, Eliza A |
| 14 | 17-Dec-2014 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. | Yeung, David T; Osborn, Michael P; White, Deborah L; Branford, Susan; Braley, Jodi A; Herschtal, Alan; Kornhauser, Michael; Issa, Samar; Hiwase, Devendra K; Hertzberg, Mark; Schwarer, Anthony P ; Filshie, Robin; Arthur, Christopher K; Kwan, Yiu Lam; Trotman, Judith; Forsyth, Cecily J; Taper, John; Ross, David M; Beresford, Jennifer; Tam, Constantine; Mills, Anthony K; Grigg, Andrew P ; Hughes, Timothy P |
Loading...
2
0
20
0
false